文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性软组织肉瘤患者的PSMA表达与PSMA PET/CT显像:一项前瞻性研究结果

PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-27

这项前瞻性单中心可行性研究纳入25例转移性软组织肉瘤患者,11例(44%)免疫组化显示PSMA高表达;其中5例接受[18F]-JK-PSMA-7 PET/CT,3例病灶摄取达SUVmax>8,但所有转移灶摄取高度异质(中位SUVmax=3.8,范围0.5-16.7),研究因此提前终止。作者认为PSMA表达与摄取高度异质,未来应用PSMA靶向放射性配体治疗需深入理解PSMA生物学并改进患者筛选标准。

要点

  • 25例转移性软组织肉瘤中11例(44%)免疫组化PSMA高表达。
  • 5例接受[18F]-JK-PSMA-7 PET/CT,3例病灶SUVmax>8(10.7-16.7)。
  • 所有转移灶摄取高度异质(中位SUVmax=3.8,范围0.5-16.7),研究提前终止。

核心结论

  • 转移性软组织肉瘤的PSMA表达与PSMA示踪剂摄取高度异质。
  • 作者认为,未来在该病中应用PSMA靶向放射性配体治疗,需深入理解PSMA生物学并改进患者筛选标准。

研究设计与样本

  • 前瞻性单中心可行性研究,纳入成人转移性软组织肉瘤患者,要求可测量病灶(病灶直径>1 cm)、有活检/切除材料、ECOG/WHO体能状态0-2分,且未接受过系统治疗、治疗中/后进展、或末次给药>8周后疾病稳定/部分缓解。
  • 对既往活检或切除材料行PSMA免疫组化染色;PSMA高表达者行[18F]-JK-PSMA-7 PET/CT,以SUVmax>8定义为摄取充分。
  • 共纳入25例患者。

主要发现

  • 25例中11例(44%)PSMA高表达:平滑肌肉瘤4/11、去分化脂肪肉瘤3/4、未分化多形性肉瘤2/5、黏液纤维肉瘤1/2、恶性外周神经鞘瘤1/1。
  • 11例中5例同意行[18F]-JK-PSMA-7 PET/CT,其中3例病灶摄取充分(SUVmax 10.7-16.7)。
  • 所有转移灶摄取高度异质(中位SUVmax=3.8;范围0.5-16.7),提示这些患者不太可能从PSMA靶向治疗中充分获益。
  • 研究因此提前终止。

关键数值与推荐

  • PSMA高表达者行[18F]-JK-PSMA-7 PET/CT,摄取充分定义为SUVmax>8。
  • 可测量病灶定义为病灶直径>1 cm。
  • 入组要求ECOG/WHO体能状态0-2分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究提前终止。
  • 作者认为,未来应用PSMA靶向放射性配体治疗需深入理解PSMA生物学并改进患者筛选标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA) expression has been observed in a subset of soft tissue sarcomas, mainly in the neovascular endothelial cells. This feasibility study aimed to evaluate PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma, providing important insights for potential future exploration of PSMA-targeted radioligand therapy. METHODS: This prospective single-center study included adult patients with metastatic soft tissue sarcoma, with measurable disease (lesion diameter > 1 cm), available biopsy/resection material, ECOG/WHO performance status of 0-2 and either no prior systemic treatment, progressive disease during/after treatment, or stable disease/partial response with the last dose > 8 weeks prior. Immunohistochemical PSMA staining was performed on previously obtained biopsy or resection material. In case of high PSMA expression, a [18F]-JK-PSMA-7 PET/CT scan evaluated tracer uptake, with adequate uptake defined as SUVmax > 8. RESULTS: Of 25 included patients, 11 (44%) had high PSMA expression: 4/11 leiomyosarcomas, 3/4 dedifferentiated liposarcomas, 2/5 undifferentiated pleomorphic sarcomas, 1/2 myxofibrosarcomas and 1/1 malignant peripheral nerve sheath tumour. Five of 11 patients agreed to a [18F]-JK-PSMA-7 PET/CT, of which 3 had lesions that showed adequate tracer uptake (SUVmax 10.7-16.7). However, uptake across all metastatic lesions was highly heterogeneous (median SUVmax = 3.8; range 0.5-16.7), indicating that these patients are unlikely to benefit sufficiently from PSMA-targeted therapy. The study was therefore terminated prematurely. CONCLUSION: PSMA expression and PSMA tracer uptake in metastatic soft tissue sarcoma were highly heterogeneous. A deeper understanding of PSMA biology and improved patient selection criteria are essential for future application of PSMA-targeted radioligand therapy in this disease. TRIAL REGISTRATION: clinicaltrials.gov, NCT05522257. Registered 31-08-2022.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kleiburg F, van der Hulle T, Gelderblom H, et al. PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40146266. doi:10.1007/s00259-025-07224-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。